Abiomed, Inc. (ABMD) Tops Q2 Views; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Join SI Premium – FREE
Abiomed, Inc. (NASDAQ: ABMD) reported Q2 EPS of $0.09, $0.18 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $29.5 million versus the consensus estimate of $27.7 million.
The stock was halted to report the results.
The stock was halted to report the results.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- The LGL Group (LGL) Misses Q2 EPS by 8c
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
Create E-mail Alert Related Categories
Earnings, Guidance, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
